Vbi Vaccines Inc CS (VBIV) |
|
3.64 -0.12 (-3.19%)
|
08-14 16:00 |
|
Open: |
3.74 |
Pre. Close: |
3.76 |
|
High:
|
3.7847 |
Low:
|
3.505 |
|
Volume:
|
4,014,585 |
Market Cap:
|
842M |
|
|
|
|
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.791 - 3.812 |
3.812 - 3.829 |
|
Low:
|
3.448 - 3.476 |
3.476 - 3.499 |
|
Close:
|
3.597 - 3.64 |
3.64 - 3.676 |
|
Technical analysis |
as of: 2020-08-14 4:35:23 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 6.48 One year: 8.09 |
| Support: |
Support1: 3.31 Support2: 2.75 |
| Resistance: |
Resistance1: 5.55 Resistance2: 6.93 |
| Pivot: |
4.10 |
| Moving Average: |
MA(5): 3.74 MA(20): 4.46
MA(100): 2.58  MA(250): 1.59 |
| MACD: |
MACD(12,26): -0.06 Signal(9): 0.11 |
| Stochastic oscillator: |
%K(14,3): 15.41 %D(3): 11.33 |
| RSI: |
RSI(14): 43.89 |
| 52-week: |
High: 6.93 Low: 0.47 Change(%): 453.8 |
| Average Vol(K): |
3-Month: 1306143 10-Days: 828492 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.VBIV has closed above bottom band by 17.6%. Bollinger Bands are 0.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 05 Aug 2020
PREVIEW-Golf-A PGA Championship like no other comes to San Francisco - Nasdaq
Wed, 05 Aug 2020
BUZZ-U.S. STOCKS ON THE MOVE-Oasis Petroleum, Humana, Triumph Group, Teladoc Health - Nasdaq
Wed, 05 Aug 2020
Bolsonaro says Brazil will send help to blast-stricken Lebanon - Nasdaq
Wed, 05 Aug 2020
Wall Street gains on Disney's surprise profit, fiscal aid hopes - nasdaq.com
Wed, 15 Apr 2020
VBI Vaccines - Consenus Indicates Potential 650.0% Upside - DirectorsTalk Interviews
Thu, 05 Sep 2019
VBI Vaccines to Present at the H.C. Wainwright 21st Annual Global Investment Conference - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ Capital Market |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
231 |
| Shares Float (M) |
150 |
|
% Held by Insiders
|
5.26 |
|
% Held by Institutions
|
44.45 |
|
Shares Short (K)
|
10,880 |
|
Shares Short P. Month (K)
|
6,500 |
Stock Financials |
|
EPS
|
-0.350 |
|
EPS Est This Year
|
-0.890 |
|
EPS Est Next Year
|
-1.010 |
|
Book Value (p.s.)
|
0.420 |
|
Profit Margin
|
|
|
Operating Margin
|
-1832.21 |
|
Return on Assets (ttm)
|
-22.3 |
|
Return on Equity (ttm)
|
-60.3 |
|
Qtrly Rev. Growth
|
15.3 |
|
Gross Profit (p.s.)
|
-0.025 |
|
Sales Per Share
|
0.010 |
|
EBITDA (p.s.)
|
-0.174 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-42 |
|
Levered Free Cash Flow (M)
|
-30 |
Stock Valuations |
|
PE Ratio
|
-10.40 |
|
PEG Ratio
|
|
|
Price to Book value
|
8.67 |
|
Price to Sales
|
368.23 |
|
Price to Cash Flow
|
-19.83 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2012-12-27 |
|
Ex-Dividend Date
|
2012-02-04 |
|
7 Binary Options
|
|
Your Ad Here
|
|
